Epidermolysis Bullosa.
Khanna D, Bardhan A.
2024 Jan 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Dystrophic Epidermolysis Bullosa.
Lucky AW, Pope E, Crawford S.
2006 Aug 21 [updated 2025 Aug 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Clinical practice guidelines: Oral health care for children and adults living with epidermolysis bullosa.
Krämer S, Lucas J, Gamboa F, Peñarrocha Diago M, Peñarrocha Oltra D, Guzmán-Letelier M, Paul S, Molina G, Sepúlveda L, Araya I, Soto R, Arriagada C, Lucky AW, Mellerio JE, Cornwall R, Alsayer F, Schilke R, Antal MA, Castrillón F, Paredes C, Serrano MC, Clark V.
Spec Care Dentist. 2020 Nov;40 Suppl 1(Suppl 1):3-81. doi: 10.1111/scd.12511.
Dystrophic epidermolysis bullosa.
Burkhart CG, Ruppert ES.
Clin Pediatr (Phila). 1981 Aug;20(8):493-6. doi: 10.1177/000992288102000801.
Image Gallery: Multiple localized lipoatrophy in recessive dystrophic epidermolysis bullosa.
Nohara T, Fujita Y, Takashima S, Natsuga K, Shimizu H.
Br J Dermatol. 2019 Mar;180(3):e64. doi: 10.1111/bjd.17356.
Epidermolysis Bullosa-A Different Genetic Approach in Correlation with Genetic Heterogeneity.
Pânzaru MC, Caba L, Florea L, Braha EE, Gorduza EV.
Diagnostics (Basel). 2022 May 27;12(6):1325. doi: 10.3390/diagnostics12061325.
Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.
Zorina A, Zorin V, Isaev A, Kudlay D, Manturova N, Ustugov A, Kopnin P.
Int J Mol Sci. 2024 Sep 24;25(19):10270. doi: 10.3390/ijms251910270.
Congenital localized absence of skin (Bart syndrome) in a patient with dominant dystrophic epidermolysis bullosa.
Ramos FJM, Corpas TD, Corrales AE, Puchades AM.
An Pediatr (Engl Ed). 2023 Dec;99(6):447-448. doi: 10.1016/j.anpede.2023.04.016. Epub 2023 Aug 17.
Integrated Management Strategies for Epidermolysis Bullosa: Current Insights.
Sait H, Srivastava S, Saxena D.
Int J Gen Med. 2022 May 24;15:5133-5144. doi: 10.2147/IJGM.S342740. eCollection 2022.
Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-beta signalling.
Macaulay ARK, Yang J, Price MA, Forster CL, Riddle MJ, Ebens CL, Albert FW, Giubellino A, McCarthy JB, Tolar J.
Br J Dermatol. 2024 Dec 23;192(1):104-117. doi: 10.1093/bjd/ljae295.
